Real-life effectiveness (and cost impact) evaluation of fixed-dose combination fluticasone propionate/formoterol (Flutiform®) for the management of asthma in a routine UK primary care population – Phase 2 (Real-life effectiveness of Flutiform - Phase 2)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/8885
• EU PAS number:
  EUPAS7641
• Study ID:
  8885
• Official title and acronym:
  Real-life effectiveness (and cost impact) evaluation of fixed-dose combination fluticasone propionate/formoterol (Flutiform®) for the management of asthma in a routine UK primary care population – Phase 2 (Real-life effectiveness of Flutiform - Phase 2)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  To evaluate the comparative effectiveness of changing real-life asthma patients from fluticasone propionate / salmeterol (Seretide®, FP/SAL) to fluticasone propionate / formoterol (Flutiform®, FP/FOR) in asthma patients.
• Study status:
  Finalised

Research institutions and networks

Institutions

Research in Real Life

Study timelines

Date when funding contract was signed

Planned: 25/07/2012

Actual: 25/07/2012

Study start date

Planned: 03/02/2014

Actual: 03/02/2014

Data analysis start date

Planned: 18/08/2014

Actual: 01/11/2014

Date of final study report

Planned: 28/11/2014

Actual: 31/12/2014

Sources of funding

Pharmaceutical company and other private sector 

Other

More details on funding

Napp Pharmaceuticals, RIRL

Study protocol

Initial protocol

2014_10_16 RiRL Study Protocol_phase2_ENCEPP

Regulatory

• Was the study required by a regulatory body?:
  No